Liposomes as Therapeutic Vehicles: Advancing Targeted Drug Delivery in Healthcare

Year : 2024 | Volume : 11 | Issue : 03 | Page : 39 46
    By

    Varsha R. Gaikwad,

  • Shaikh Sabiya,

  • Sahil Khan,

  • Tariq Choudhary,

  • Aayush Kesarwani,

  • Nehad Ansari,

  • Anzal Ansari,

  • Ambika Nand Jha,

  1. Assistant Professor, Department of Pharmacognosy, Shri Pandit Baburao Chaughule College of Pharmacy, Maharashtra, India
  2. Assistant Professor, Department of Pharmaceutical Chemistry, Shri Pandit Baburao Chaughule College of Pharmacy, Maharashtra, India
  3. Students, B.Pharm, Shri Pandit Baburao Chaughule College of Pharmacy, Bhiwandi, Maharashtra, India
  4. Students, B.Pharm, Shri Pandit Baburao Chaughule College of Pharmacy, Bhiwandi, Maharashtra, India
  5. Students, B.Pharm, Shri Pandit Baburao Chaughule College of Pharmacy, Bhiwandi, Maharashtra, India
  6. Students, B.Pharm, Shri Pandit Baburao Chaughule College of Pharmacy, Bhiwandi, Maharashtra, India
  7. Students, B.Pharm, Shri Pandit Baburao Chaughule College of Pharmacy, Bhiwandi, Maharashtra, India
  8. Assistant Professor, Department of Pharmacy Practice, School of Pharmacy, Sharda University, Uttar Pradesh, India

Abstract

Liposomes represent an innovative approach to targeted drug delivery. These tiny, lipid-based vesicles can encapsulate medications, allowing them to travel directly to diseased cells while minimizing impact on healthy tissues. By using liposomes, medications can improve their effectiveness while reducing side effects, leading to better overall treatment results.. Their structure enables a controlled release of the drug, which can be particularly beneficial for therapies requiring sustained action. This technology holds promise for various medical applications, including cancer treatment and vaccine delivery, making it a significant advancement in improving how we administer and target therapeutic agents within the body. The unique structure of liposomes allows for controlled drug release, which is particularly advantageous for therapies necessitating sustained action over time. In the context of oncology and genetic disorders, liposomes are revolutionizing treatment paradigms. Their capacity to encapsulate various therapeutic agents, such as small molecules, proteins, and nucleic acids, allows for targeted delivery to specific tissues in need. Their unique ability to encapsulate therapeutic agents allows for targeted delivery directly to affected cells, minimizing side effects and enhancing treatment efficacy. By modifying the liposome’s surface, researchers can create formulations that selectively bind to specific cell types, making them invaluable for personalized medicine. This focused strategy enhances patient outcomes and paves the way for the development of novel therapies. As research advances, liposomes hold great promise for transforming how we approach disease treatment and management, paving the way for more effective and individualized healthcare In this article, we will delve into the intriguing history of liposomes, tracing their discovery and examining their various applications in the medical field. We’ll delve into how they function, enabling targeted delivery of drugs and enhancing treatment efficacy. Their ability to encapsulate various therapeutic agents has led to breakthroughs in treating conditions like cancer and genetic disorders. With ongoing research, liposomes continue to reveal new possibilities in personalized medicine, transforming patient care.

Keywords: Cancer treatment, Controlled release, Liposomes, Targeted drug delivery, Therapeutic agents

[This article belongs to Research & Reviews: A Journal of Drug Design & Discovery ]

How to cite this article:
Varsha R. Gaikwad, Shaikh Sabiya, Sahil Khan, Tariq Choudhary, Aayush Kesarwani, Nehad Ansari, Anzal Ansari, Ambika Nand Jha. Liposomes as Therapeutic Vehicles: Advancing Targeted Drug Delivery in Healthcare. Research & Reviews: A Journal of Drug Design & Discovery. 2024; 11(03):39-46.
How to cite this URL:
Varsha R. Gaikwad, Shaikh Sabiya, Sahil Khan, Tariq Choudhary, Aayush Kesarwani, Nehad Ansari, Anzal Ansari, Ambika Nand Jha. Liposomes as Therapeutic Vehicles: Advancing Targeted Drug Delivery in Healthcare. Research & Reviews: A Journal of Drug Design & Discovery. 2024; 11(03):39-46. Available from: https://journals.stmjournals.com/rrjoddd/article=2024/view=180452


References

  1. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):1–15. doi:10.1016/j.heliyon.2022.e09394.
  2. Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives. Mol. 2022;27(4):1372. doi:10.3390/molecules27041372.
  3. Akbarzadeh A, Rezaei-Saidabad R, Davaran S, Joo SW, Zargari N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi:10.1186/1556-276X-8-102
  4. Trucillo P, Campardelli R, Reverchon E. Liposomes: From Bangham to supercritical fluids. Proc. 2020;8(9):1022. doi:10.3390/pr8091022.
  5. Hamid MSS, Hatwar PR, Bakal RL, Kohale NB. A comprehensive review on Liposomes: As a novel drug delivery system. GSC Biol Pharm Sci. 2024;27(1):199–210. doi:30574/gscbps.2024.27.1.0121.
  6. Zafar MN, Abuwatfa WH, Husseini GA. Acoustically-activated liposomal nanocarriers to mitigate the side effects of conventional chemotherapy with a focus on emulsion-liposomes. Pharmaceutics. 2023;15(2):421. doi:10.3390/pharmaceutics15020421.
  7. Loscertales E, Mateo J, España S. A comparative study of sensitizers and liposome composition in radiation-induced controlled drug release for cancer therapy. J Liposome Res. 2024;1–12. doi:10.1080/08982104.2024.2401800.
  8. Paweletz LC, Labedzki N, Günther Pomorski T. Micro-scale quantitative analysis of sterol content in liposomes. J Liposome Res. 2024;1–8. doi:10.1080/08982104.2024.2388146.
  9. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. doi:10.1016/j.addr.2012.09.037.
  10. Hamad I, Harb AA, Bustanji Y. Liposome-based drug delivery systems in cancer research: An analysis of global landscape efforts and achievements. Pharmaceutics. 2024;16(3):400. doi:10.3390/pharmaceutics16030400.
  11. Tretiakova DS, Vodovozova EL. Liposomes as adjuvants and vaccine delivery systems. Biochem (Mosc) Suppl Ser A Membr Cell Biol. 2022;16(1):1-20. doi:10.1134/S1990747822020076.
  12. Olusanya TOB, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. Liposomal drug delivery systems and anticancer drugs. Mol. 2018;23(4):907. doi:10.3390/molecules23040907.
  13. Shrestha S. Liposomal formulations in cancer immunotherapy: Recent advancements and future challenges. Cancer Immunol Immunother 2019;68(4):603–616.
  14. Mahmood A, Bernkop- Schnürch A. SEDDS: A game changing approach for the oral administration of hydrophilic macromolecular drugs. Adv Drug Deliv Rev. 2019;142:91–101. doi:10.1016/j.addr.2018.07.001.
  15. Reimondez-Troitiño S, González-Aramundiz JV, Ruiz-Bañobre J, López-López R, Alonso MJ, Csaba N, et al. Versatile protamine nanocapsules to restore miR-145 levels and interfere tumor growth in colorectal cancer cells. Eur J Pharm Biopharm. 2019;142:449–459. doi:10.1016/j.ejpb.2019.07.016.
  16. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003. doi:10.1038/nmat3681.
  17. D’Apolito R, Tomaiuolo G, Taraballi F, Minardi S, Kirui D, Liu X, Cevenini A, Palomba R, Ferrari M, Salvatore F, Tasciotti E. Red blood cells affect the margination of microparticles in synthetic microcapillaries and intravital microcirculation as a function of their size and shape. J Control Release. 2015;217:263–272. doi:10.1016/j.jconrel.2015.09.013.
  18. Vyas SP, Singh S. Nanoparticles for targeted and controlled drug delivery. Drug Deliv Transl Res. 2012;2(5):241–256.
  19. Raghavan K, Chen J, Yu Y. Nanocarriers for the delivery of drugs: a review. Front Pharmacol. 2016;7. doi:10.3389/fphar.2016.00391.
  20. Klibanov AL, Maruyama K, Beckerleg AM. Liposome-mediated drug delivery: a critical review. J Drug Target. 2014;22(6):481–490. doi:10.3109/1061186X.2014.900691.
  21. Sjöholm E, Sandler N. Additive manufacturing of personalized orodispersible warfarin films. Int J Pharm. 2019;564:117–123. doi:10.1016/j.ijpharm.2019.04.018.
  22. Hajj K, Whitehead K. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;17056. doi:10.1038/natrevmats.2017.56.
  23. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–60. doi:10.1038/nrd1632.
  24. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133–149. doi:10.2147/ijn.s596.
  25. Miyazaki Y, Uchino T, Kagawa Y. Compounding of low-dose pharmaceutical powders using a planetary centrifugal mixer. J Drug Deliv Sci Technol. 2019;52:103–109. doi:10.1016/j.jddst.2019.04.007.
  26. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation. Clin Pharmacokinetic. 2003;42(5):403–417. doi:10.2165/00003088-200342050-00001.
  27. Szoka FC. Liposomal Drug Delivery: Current Status and Future Prospects. 1st Boca Raton, FL: CRC Press; 2019. 845–890.
  28. Fulton MD, Najahi-Missaoui W. Liposomes in cancer therapy: How did we start and where are we now. Int J Mol Sci. 2023;24(7):6615. doi:10.3390/ijms24076615.
Regular Issue Subscription Review Article
Volume 11
Issue 03
Received 16/10/2024
Accepted 21/10/2024
Published 29/10/2024
319

Login


My IP

PlumX Metrics